{
    "clinical_study": {
        "@rank": "154680", 
        "arm_group": [
            {
                "arm_group_label": "Placebo for benfotiamine", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months"
            }, 
            {
                "arm_group_label": "Benfotiamine", 
                "arm_group_type": "Experimental", 
                "description": "Treatment with benfotiamine 600 mg/day for 3 months followed by 300 mg/day for 9 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the present study is to assess before, as well as 6 and 12 months following a\n      therapy with benfotiamine the influence of therapy on intraepidermal nerve fiber density\n      (skin biopsy) and neuropathic symptoms and deficits in people with type 1 or 2 diabetes\n      mellitus and diabetic sensomotoric neuropathy."
        }, 
        "brief_title": "Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Neuropathies", 
        "condition_browse": {
            "mesh_term": "Diabetic Neuropathies"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have type 1 or type 2 diabetes mellitus based on the disease diagnostic criteria\n             (WHO) classification on ongoing insulin or/and oral antidiabetic therapy with a\n             stable regimen for the previous 3 months\n\n          -  Male or female subjects aged between 18 and 75 years, inclusive\n\n          -  Have an HbA1c level \u2264 9.5% without optimizing potential\n\n          -  mTCNS (modified Toronto Clinical Neuropathy Score) \u2265 (above or equal to) 6) OR (a\n             score on the MNSI (Michigan Neuropathy Screening Instrument)questionnaire of \u22654 or a\n             score on the MNSI examination \u22652.5)\n\n          -  Medical history without major pathology (with the exception of type 2 diabetes) as\n             judged by the investigator, especially no major peripheral artery disease.\n\n          -  Body mass index (BMI) between 25 and 45kg/m2, both inclusive\n\n        Exclusion Criteria:\n\n          -  Subjects with secondary forms of diabetes such as due to pancreatitis.\n\n          -  Current or previous treatment (less than 6 months) with benfotiamine, B-vitamins,\n             vitamin B complex, alpha lipoic acid or actovegin.\n\n          -  Have any contraindications, known allergy, or hypersensitivity to benfotiamine.\n\n          -  Have any contraindications, known allergy, or hypersensitivity to local anesthetics.\n\n          -  Neuropathy by other origin than diabetes.\n\n          -  Other severe pain that might impair the assessment of neuropathic pain.\n\n          -  Treatment with more than one of following: tricyclic antidepressants, serotonin\n             norepinephrine reuptake inhibitors, anticonvulsants, class I antiarrhythmics with\n             Na-channel inhibition (mexiletine, flecainid, propafenon and others) or neuroleptics\n             in patients receiving these drugs for neuropathic pain."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01868191", 
            "org_study_id": "WOE_2013_SB"
        }, 
        "intervention": [
            {
                "arm_group_label": "Benfotiamine", 
                "description": "Treatment with 600 mg/day for the first 3 months followed by 300 mg/day for 9 months", 
                "intervention_name": "Benfotiamine", 
                "intervention_type": "Drug", 
                "other_name": "Milgamma protekt"
            }, 
            {
                "arm_group_label": "Placebo for benfotiamine", 
                "description": "Treatment with placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months", 
                "intervention_name": "Placebo for benfotiamine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Benphothiamine", 
                "Thiamine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetes", 
            "Neuropathy"
        ], 
        "lastchanged_date": "May 30, 2013", 
        "location": {
            "contact": {
                "email": "helga.zeller@gmx.de", 
                "last_name": "Helga Zeller-Stefan, MD", 
                "phone": "+492011788892"
            }, 
            "facility": {
                "address": {
                    "city": "Essen", 
                    "country": "Germany", 
                    "state": "NRW", 
                    "zip": "45136"
                }, 
                "name": "Diabetes Schwerpunktpraxis"
            }, 
            "investigator": [
                {
                    "last_name": "Alin O Stirban, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Helga Zeller-Stefan, MD, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)and Diabetic Neuropathy in Subjects With Sensorimotor Diabetic Polyneuropathy: a Double-blind, Randomized, Placebo-controlled Parallel Group Pilot Study Over 12 Months.", 
        "overall_contact": {
            "email": "alin.stirban@profil.com", 
            "last_name": "Alin O Stirban, MD, PhD", 
            "phone": "+4921314018", 
            "phone_ext": "486"
        }, 
        "overall_official": {
            "affiliation": "Diabetes Schwerpunktpraxis", 
            "last_name": "Alin O Stirban, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in intraepidermal nerve fiber density", 
            "safety_issue": "No", 
            "time_frame": "6 and 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01868191"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Diabetes Schwerpunktpraxis", 
            "investigator_full_name": "Ovidiu Alin Stirban", 
            "investigator_title": "Dr. med.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Following questionnaires will be used to assess neuropathic symptoms: modified Toronto Clinical Neuropathy Score and Michigan Neuropathy Screening Instrument", 
                "measure": "Change in neuropathic symptoms", 
                "safety_issue": "No", 
                "time_frame": "3, 6 and 12 months"
            }, 
            {
                "description": "A score will be calculated at each timepoint using the Michigan Neuropathy Screening Instrument", 
                "measure": "Change in neuropathic deficits", 
                "safety_issue": "No", 
                "time_frame": "3, 6 and 12 months"
            }
        ], 
        "source": "Diabetes Schwerpunktpraxis", 
        "sponsors": {
            "collaborator": {
                "agency": "Woerwag Pharma GmbH and Co. KG", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Diabetes Schwerpunktpraxis", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}